Anle138b

Name: Anle138b
Brand: DC Chemicals
SKU: DC10168
Price: 400.0 USD

Pack size & price

USD

Ready-made solution

Total$400

We match the best price and quality on market.

Product overview

Description & Application

Anle138b is an aggregation-modulating research compound studied in α-synucleinopathies. Published mouse data connect reduced oligomer burden with neuronal and motor outcomes.

Parameter	Value
Chemical Name	Anle138b
CAS No.	882697-00-9
Synonyms	Anle138b; Anle-138b; 3-(1,3-Benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole; 5-(1,3-Benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole; Anle 138b; CID 44608289; BCP32558; Anle138b, >=98% (HPLC); NSC805132; s6782; DB13927; 3-(1,3-Benzodioxole-5-yl)-5-(3-bromophenyl)-1H-pyrazole; 3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole
Formula	C16H11BrN2O2
M.Wt	343.1747
SMILES	BrC1=C([H])C([H])=C([H])C(=C1[H])C1C([H])=C(C2C([H])=C([H])C3=C(C=2[H])OC([H])([H])O3)N([H])N=1
Purity	On request
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

α-Synuclein aggregation · Literature evidence

Biological Activity

Anle138b is an aggregation-modulating research compound studied in α-synucleinopathies. Published mouse data connect reduced oligomer burden with neuronal and motor outcomes. Anle138b was supplied in chow at 0.6 g/kg food. This concentration is not a dose per kilogram of animal body weight.

In Vitro

No separate compound-specific cell or biochemical result is available from the sources summarized here.

In Vivo

Endpoint	Model / conditions / source	Reported result
Study design	PLP-α-syn transgenic mouse model of multiple system atrophy; treatment from 2 months of age for 5 months. [1], Methods	Anle138b was supplied in chow at 0.6 g/kg food. This concentration is not a dose per kilogram of animal body weight.
Motor and neuronal outcomes	Anle138b monotherapy, n=12; vehicle, n=10. [1], Results	Improved gait abnormalities and preserved nigral dopaminergic neurons compared with vehicle.
Brain pathology	α-Synuclein oligomer and microglial measurements in treated mice. [1]	Reduced oligomer burden was accompanied by decreased microglial activation.
Combination comparison	Anle138b combined with PD03 immunotherapy; separate treatment arm. [1]	Brain IgG binding was lower than with PD03 alone. The combination should not be described as uniformly superior to monotherapy.